Incidence, prognostic value and management of vascular complications with transfemoral transcatheter aortic valve implantation

2011 ◽  
Vol 7 (3) ◽  
pp. 321-331 ◽  
Author(s):  
Francesco Saia ◽  
Barbara Bordoni ◽  
Cinzia Marrozzini ◽  
Cristina Ciuca ◽  
Carolina Moretti ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Prognostic Value ◽  
Vascular Complications ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Management and Prevention of Vascular Complications Related to Transcatheter Aortic Valve Implantation and Aortic Aneurysm Repair Procedures – A Technical Note

2010 ◽  
Vol 5 (1) ◽  
pp. 81
Author(s):  
Andrea Pacchioni ◽  
Dimitris Nikas ◽  
Carlo Penzo ◽  
Salvatore Saccà ◽  
Luca Favero ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Aneurysm ◽  
Transcatheter Aortic Valve Implantation ◽  
Severe Aortic Stenosis ◽  
Vascular Complications ◽  
Technical Note ◽  
Closure Device ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Transcatheter aortic valve implantation (TAVI) and endovascular aortic repair (EVAR) are increasingly being used as therapeutic options for patients with severe aortic stenosis who are ineligible for surgery and who have aortic aneurysm with suitable anatomical features. These procedures can be associated with severe complications, especially related to vascular access and the use of a large introducer sheath (from 18 to 24 French [Fr]). In this article we describe possible vascular complications emerging during TAVI and EVAR and their appropriate management, beginning with patient selection, the correct way to perform vessel puncture and the use of a vascular closure device, up to the recently proposed cross-over technique, which is thought to minimise the risk of dangerous consequences of vascular damage.

scholarly journals Prognostic value of the H 2 FPEF score in patients undergoing transcatheter aortic valve implantation

2020 ◽  
Author(s):  
Sebastian Ludwig ◽  
Costanza Pellegrini ◽  
Alina Gossling ◽  
Tobias Rheude ◽  
Lisa Voigtländer ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Prognostic Value ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

Prognostic value of body mass index in transcatheter aortic valve implantation: A “J”-shaped curve

2017 ◽  
Vol 232 ◽  
pp. 342-347 ◽  
Author(s):  
Rocío González-Ferreiro ◽  
Antonio J. Muñoz-García ◽  
Diego López-Otero ◽  
Pablo Avanzas ◽  
Isaac Pascual ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Aortic Valve ◽  
Body Mass ◽  
Transcatheter Aortic Valve Implantation ◽  
Prognostic Value ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

scholarly journals Evolution of transcatheter aortic valve implantation over 7 years: results of a prospective single-centre registry of 2000 patients in a large municipal hospital (TAVIK Registry)

BMJ Open ◽  
2018 ◽  
Vol 8 (10) ◽  
pp. e022574 ◽  
Author(s):  
Gerhard Schymik ◽  
Valentin Herzberger ◽  
Jens Bergmann ◽  
Peter Bramlage ◽  
Lars O Conzelmann ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Transcatheter Aortic Valve Implantation ◽  
Severe Aortic Stenosis ◽  
Vascular Complications ◽  
Rapid Progression ◽  
Single Centre ◽  
Severe Aortic Regurgitation ◽  
Transcatheter Aortic Valve ◽  
Aortic Valve Implantation ◽  
Valve Implantation

ObjectivesUse of transcatheter aortic valve implantation (TAVI) to treat severe aortic stenosis (AS) has gained popularity, accompanied by an evolution of patient and clinical factors. We aimed to characterise changes and evaluate their impact on outcomes.SettingIn this single-centre, German TAVIK registry patients undergoing TAVI between 2008 and 2015 were documented prospectively.Participants/interventions2000 consecutive patients with AS undergoing TAVI were divided in four cohorts. 500 patients underwent TAVI in each of the following time bins: April 2008 to July 2010 (cohort I), July 2010 to April 2013 (cohort II), April 2012 to October 2013 (cohort III) and October 2013 to March 2015 (cohort IV).ResultsThe mean age was 81.8 years, without significant variation across cohorts. Compared with cohort I, prior MI (5.4%vs11.0%; p<0.001) and New York Heart Association class IV (10.0%vs3.6%; p<0.001) were less common in cohort IV. Across cohorts, there was a fall in EuroSCORE (24.3%–18.7%), frailty (48.4%–17.0%) and use of transapical access (43.6%–29.0%), while transfemoral access increased (56.4%–71.0%; p<0.001 for each). Periprocedurally, there was a fall in moderate/severe aortic regurgitation (3.2%–0.0%) and rate of unplanned cardiopulmonary bypass (4.0%–1.0%; both p<0.001). A similar trend applied to 30-day rate of major vascular complications (5.2%–1.8%; p=0.006), life-threatening bleeding (7.0%–3.0%; p<0.001) and cardiovascular mortality (4.4%–1.8%; p=0.020). One-year post-TAVI, mortality and stroke rates did not differ.ConclusionsEvolution of TAVI between 2008 and 2015 saw a trend towards its usage in lower risk patients and rapid progression towards improved safety. Evaluation and refinement should now continue to further lessen stroke and pacemaker rates.

Sign in / Sign up

Export Citation Format

Share Document